No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AXSM240517C80000
- 0.40
- +0.15+60.00%
15min DelayTrading May 14 14:15 ET
0.40High0.25Low
0.30Open0.25Pre Close29 Volume460 Open Interest80.00Strike Price1.06KTurnover43.92%IV5.28%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.40Time Value100Contract SizeAmericanOptions Type0.1515Delta0.0725Gamma304.90Leverage Ratio-0.1110Theta0.0011Rho46.19Eff Leverage0.0173Vega
Intraday
- 5D
- 1D
News
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Axsome Therapeutics, Inc., a biopharmaceutica
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Axsome Therapeutics Price Target Cut to $106.00/Share From $109.00 by Mizuho
Axsome Therapeutics Price Target Cut to $106.00/Share From $109.00 by Mizuho
Axsome Therapeutics Is Maintained at Buy by Mizuho
Axsome Therapeutics Is Maintained at Buy by Mizuho
Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $106
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $109 to $106.
Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating
Axsome Therapeutics (AXSM) has an average rating of buy and price targets ranging from $97 to $190, according to analysts polled by Capital IQ.
Comments
$Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $Axsome Therapeutics(AXSM.US$ $Macrogenics(MGNX.US$
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
16
5
$Pfizer(PFE.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$ Phase 3
$Aquestive Therapeutics(AQST.US$ Phase 3
$Jaguar Health(JAGX.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$Johnson & Johnson(JNJ.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$ Phase 3
$Aquestive Therapeutics(AQST.US$ Phase 3
$Jaguar Health(JAGX.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$Johnson & Johnson(JNJ.US$ Phase 3
8
1
1. $Annovis Bio(ANVS.US$
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics(AXSM.US$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics(GTHX.US$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics(CRNX.US$
• Ph 3 data (PATHFND...
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics(AXSM.US$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics(GTHX.US$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics(CRNX.US$
• Ph 3 data (PATHFND...
7
🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
16
The strong revenue growth mirrors the robust share price gain. Top performers like Axsome Therapeutics can continue winning for decades. This seems like a good opportunity, despite the already positive sentiment.
Read more
Salmon Klein : are you in $Macrogenics (MGNX.US)$ ? tell me when good to jump in
MangoXXXX Salmon Klein: Now
SlowndEasyTrades Salmon Klein: Do your own research , I think hovering in bottom and buy signal from pattern about to begin , do not follow me blindly my
Salmon Klein SlowndEasyTrades: I am waiting to reach 14.8 or so, but I am busy working, if it reached the bottom and you are in...any good feedback is always very welcomed bro...just that so thanks
SlowndEasyTrades Salmon Klein: Double higher bottom in intra-day might not hit below 14ish or if so still chance for 2 more trading sideways days, I am almost 25% down ( reason holding beyond top) anyway